Brief: Abbvie Submits EMA Application For Skyrizi Subcutaneous Induction In Adult Crohn's Disease
27/08/2026 07:33
BRIEF-Abbvie Submits EMA Application For Skyrizi Subcutaneous Induction In Adult Crohn's Disease Aug 27 (Reuters) - AbbVie Inc. ABBV.N:
ABBVIE SUBMITS REGULATORY APPLICATION TO EMA FOR SKYRIZI® (RISANKIZUMAB) SUBCUTANEOUS INDUCTION FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
ABBVIE SUBMITS REGULATORY APPLICATION TO EMA FOR SKYRIZI® (RISANKIZUMAB) SUBCUTANEOUS INDUCTION FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
Source text: ID:nPn6d84CPa
Further company coverage: ABBV.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96